Skip to main content
Oxford University Hospitals NHS Foundation Trust

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Patients and visitors must wear a face covering in our hospitals.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Genetic testing for Brugada syndrome (R128)

Brugada syndrome is an inherited arrhythmogenic disorder, characterised by ST-segment elevation on ECG, incomplete right bundle-branch block, and increased risk of sudden cardiac death as the result of ventricular fibrillation (VF) often during sleep.

Background information

SCN5A is considered to be the only definitive Brugada syndrome gene and is the only gene screened. Genetic testing of SCN5A has a clinical sensitivity of approximately 20 percent.

Both missense and copy number variants have been identified.

NHSE funded test referrals should meet the relevant NHSE eligibility criteria (pdf).

Testing strategy

Clinically affected probands:

R128 - Singleton analysis of one gene. Data from the entire coding region of the main transcript of SCN5A is always included.

Targeted analysis for known / previously reported familial variants:

  • Family testing in clinically unaffected family members at risk of inheriting a previously reported familial pathogenic variant (R242)
  • Diagnostic confirmation in individuals at risk of inheriting a previously reported familial pathogenic variant and clinically suspected of having the familial condition (R240)
  • Segregation studies in affected family members to aid variant interpretation (R375)
  • Prenatal diagnosis for families with a pathogenic or likely pathogenic variant identified (R240 and R321 Maternal cell contamination)

Target reporting times

  • 42 calendar days for diagnostic screening of affected individuals
  • 42 calendar days for diagnostic confirmation in individuals at risk of inheriting a previously reported familial pathogenic variant and clinically suspected of having the familial condition (R240)
  • 14 calendar days for presymptomatic testing of clinically unaffected family members at risk of inheriting a previously reported familial pathogenic variant (R242)

Turnaround times for genetic / genomic testing

Sample requirements and referral information

All non NHSE referrals should be accompanied by a completed referral form.

Requesting specialties:

  • Cardiology
  • Clinical Genetics
  • Paediatrics
  • Electrophysiology
  • Pathology
  • Coroners

Specimen requirements and referring samples

Price list for non NHSE referrals (pdf)

Contact us

Oxford Genetics Laboratories - Contact us

Specific enquiries

Email: OxfordCardiac@nhs.net

Last reviewed:02 August 2021